NOVN Novan Inc.

2.4
-0.11  -4%
Previous Close 2.51
Open 2.52
Price To Book -3.08
Market Cap 62,567,362
Shares 26,069,734
Volume 23,608
Short Ratio
Av. Daily Volume 73,156

Drug Information

Drug catalyst information is displayed when you hover over the stage bar graph.

Phase 2 data released November 29, 2016. Primary endpoint met.
SB206
Human papillomavirus (HPV)
Phase 2 data released April 12, 2017. Primary endpoint met.
SB208
Fungal infections
Phase 3 top-line data released January 27, 2017. Met one of three co-primary endpoints in NI-AC301 trial. Met all endpoints in NI-AC302 trial. Additional Phase 3 trial required.
SB204
Acne vulgaris
Phase 3 data due early 1Q 2020 or before.
SB206
Molluscum contagiosum skin infection
Phase 2 trial to be initiated 4Q 2019.
SB414
Atopic Dermatitis

Latest News

  1. Lean-running Triangle drugmaker to drastically shrink its office space
  2. Novan Advances Women’s Health Business Unit with Non-Dilutive Funding
  3. Novan Takes Steps to Reduce Real Estate Footprint
  4. Novan’s Phase 3 Molluscum Pivotal Program Completes Enrollment
  5. Analysts Estimate Novan (NOVN) to Report a Decline in Earnings: What to Look Out for
  6. Novan’s Drug Substance Demonstrates Inhibition of HPV-18 Virus Production
  7. Novan SB206 Phase 3 Molluscum Pivotal Program Update
  8. Does Market Volatility Impact Novan, Inc.'s (NASDAQ:NOVN) Share Price?
  9. Is Novan, Inc. (NASDAQ:NOVN) A Volatile Stock?
  10. Novan Expands External Business Partner Network
  11. Novan to Participate in JMP Securities Life Sciences Conference
  12. Novan Achieves Compliance with Nasdaq Listing Rule 5450(b)(2)(A)
  13. First Patient Enrolled and Dosed in Novan’s SB206 Phase 3 Molluscum Program
  14. Novan Announces 2019 Annual Meeting of Stockholders for July 31, 2019
  15. Executive Voice: She raises cash, and hope, for struggling Novan
  16. Is WisdomTree International High Dividend Fund (DTH) a Strong ETF Right Now?
  17. With a fresh $30 million, Durham pharma set to expand drug pipeline
  18. Novan to Present Clinical Data at Annual Meeting of the Society for Investigative Dermatology
  19. Novan adds more cash, now confident it can execute
  20. Novan Completes Funding Transaction with Ligand Pharmaceuticals